subject area of
- A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients Academic Article
- A von Willebrand factor fragment containing the D′D3 domains is sufficient to stabilize coagulation factor VIII in mice Academic Article
- Autoimmune Platelet Destruction: Idiopathic Thrombocytopenic Purpura Academic Article
- Calcium and the Fc Receptor on Human Platelets Academic Article
-
Comparative pharmacokinetics of two extended half‐life
FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? Academic Article - Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption Academic Article
-
Design and baseline characteristics of participants in the
R esearching cardiovascularE vents with aW eeklyIN cretin inD iabetes (REWIND ) trial on the cardiovascular effects of dulaglutide Academic Article - Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Academic Article
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Academic Article
-
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the
REWIND randomized trial Academic Article - Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Academic Article
- Dulaglutide slows kidney disease in type 2 diabetes − Author's reply Academic Article
- Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial Academic Article
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus Academic Article
- Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial Academic Article
- Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus Academic Article
- Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial Academic Article
- Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND Academic Article
- Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States Academic Article
- Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics Academic Article
- HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial Academic Article
- Idiosyncratic Drug-Induced Thrombocytopenia1 Academic Article
- Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products Academic Article
- Interaction of Human IgE with Fc Epsilon RI Alpha Exposes Hidden Epitopes on IgE Academic Article
- Modulation of Hepatic Granulomatous Responses by Transgene Expression of DAP12 or TREM-1-Ig Molecules Academic Article
- Monovalent Fc receptor blockade by an anti–Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity Academic Article
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin Academic Article
- Switching to extended half-life products in Canada - preliminary data Academic Article
- The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial Academic Article
- Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis Academic Article